GC Green Cross, Approval of use for 3rd therapeutic purpose of Corona plasma treatment

 GC Green Cross, 

Approval of use for 3rd therapeutic purpose 

of Corona plasma treatment

Plasma treatment for COVID-19 of GC Green Cross's was approved for a third therapeutic use. 

On the 30th, the Ministry of Food and Drug Safety approved the therapeutic use of the COVID-19 plasma treatment "GC5131A" applied by A Ju University Hospital.

Accordingly, on last 19th, followed by the first approval of Chil Gok Kyung Buk National University Hospital and the second approval of Soon Chung Hyang University Bucheon Hospital, it is used for corona patient for therapeutic purposes in medical fields other than clinical trial institutions.

A Ju University Hospital plans to use "GC5131A" to treat COVID-19 pneumonia of individual patients.

In order to treat no other means of treatment or severe life-threatening patients, the Ministry of Food and Drug Safety is operating an approval system for therapeutic purposes that allows use of drugs for clinical trials.

'GC5131A' which is being developed by GC Green Cross is currently undergoing phase 2 clinical trials. Under the approval of the Ministry of Food and Drug Safety, it can be used for patients who has no alternative treatment means.

The approval of plasma treatments for therapeutic purposes is encouraging in that treatment options have been secured for corona 19 patients who do not have alternative drugs. 

Currently, GC Green Cross is conducting phase 2 clinical trials for 60 high-risk patients at six hospitals including Joong Ang University Hospital and Samsung Seoul Hospital. Around the world, a small number of COVID-19 blood treatment drugs are being developed including a global clinical trial led by the National Institute of Health (NIH) and an Israeli pharmaceutical company Kamada.

An official from GC Green Cross said "Inquiries about the use of plasma treatments are continuing in the medical field due to successive approvals for therapeutic use. It is expected that the use of therapeutic purposes in the medical field will expand in the future."

Reference : https://bit.ly/37XDbYg